{
  "first_published_at": "2012-03-08", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON146528", 
  "title": "Teva levothyroxine 100 microgram tablets: potential reduced efficacy—suspension of marketing authorisation", 
  "tags": "{\"parsed_therapeutic\": [\"endocrinology-diabetology-metabolism\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Endocrinology, diabetology and metabolism\"]}", 
  "_document_number": 120, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/withdrawal_icon.png", 
  "therapeutic_area": [
    "endocrinology-diabetology-metabolism"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Teva levothyroxine 100 microgram tablets: potential reduced efficacy&#8212;suspension of marketing authorisation</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: March 2012</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended. The CHM review examined sporadic reports of potential reduced efficacy when switching to Teva levothyroxine from other levothyroxine products and evidence of manufacturing difficulties-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended. The CHM review examined sporadic reports of potential reduced efficacy when switching to Teva levothyroxine from other levothyroxine products and evidence of manufacturing difficultiesAs a precautionary measure while investigations are ongoing, Teva has ceased manufacture and distribution of levothyroxine 100 microgram tablets. Only the Teva and Numark brands of this product are affected by the suspension.</p>\n\n<p>Teva levothyroxine 100 microgram tablets will cease to be available in the UK within the next few weeks, and no further supplies of this product will be released for marketing. Teva is accepting returned stock via the normal channels if it is not required to meet patient needs*. Other levothyroxine 100 microgram products will continue to be available.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Prescribers should be alert to the possibility that a change in a patient&#8217;s symptoms and TSH status may be attributed to switching to Teva product from another levothyroxine product</li>\n\n<li>Certain patient groups such as pregnant women, patients with heart disease, and patients receiving treatment with levothyroxine following treatment for thyroid cancer should be monitored closely. If taking Teva tablets, they should have an early appointment with their doctor for a clinical review and blood test</li>\n\n<li>The majority of patients will be able to continue with their medication and change to a different levothyroxine product at their next prescription</li>\n\n<li>Patients who experience a significant change in symptoms especially after switching should have their TSH status reviewed and their dose of levothyroxine adjusted accordingly</li>\n\n<li>You can report suspected lack of efficacy on a Yellow Card (<a target=\"_blank\" href=\"www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>)</li>\n</ul>\n</div>\n\n<p>*Please liaise with your wholesaler or arrange for uplift via Teva&#8217;s Customer Liaison team (0800 590 502) in the usual manner if you wish to return the Teva /Numark levothyroxine 100 microgram packs.</p>\n\n<p><strong>Further information:</strong></p>\n\n<p>Central Alerting System alert for the <a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101734\">suspension of Teva levothyroxine 100 microgram tablets</a> (issued 16th February 2012)</p>\n\n<p>MHRA <a target=\"_blank\" href=\"http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON143688\">press release</a> on suspension of Teva levothyroxine</p>\n\n<p><a target=\"_blank\" href=\"/home/groups/comms-po/documents/news/con143690.pdf\">Q&#38;A document</a> on Teva levothyroxine suspension</p>\n\n<p><em>Article citation: Drug Safety Update March 2012, vol 5 issue 8: S1.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Following a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended. The CHM review examined sporadic reports of potential reduced efficacy when switching to Teva levothyroxine from other levothyroxine products and evidence of manufacturing difficultiesAs a precautionary measure while investigations are ongoing, Teva has ceased manufacture and distribution of levothyroxine 100 microgram tablets. Only the Teva and Numark brands of this product are affected by the suspension.</p>\n\n<p>Teva levothyroxine 100 microgram tablets will cease to be available in the UK within the next few weeks, and no further supplies of this product will be released for marketing. Teva is accepting returned stock via the normal channels if it is not required to meet patient needs*. Other levothyroxine 100 microgram products will continue to be available.</p>\n\n<div class=\"dull_highlight\">\n<p><strong>Advice for healthcare professionals:</strong></p>\n\n<ul>\n<li>Prescribers should be alert to the possibility that a change in a patient&#8217;s symptoms and TSH status may be attributed to switching to Teva product from another levothyroxine product</li>\n\n<li>Certain patient groups such as pregnant women, patients with heart disease, and patients receiving treatment with levothyroxine following treatment for thyroid cancer should be monitored closely. If taking Teva tablets, they should have an early appointment with their doctor for a clinical review and blood test</li>\n\n<li>The majority of patients will be able to continue with their medication and change to a different levothyroxine product at their next prescription</li>\n\n<li>Patients who experience a significant change in symptoms especially after switching should have their TSH status reviewed and their dose of levothyroxine adjusted accordingly</li>\n\n<li>You can report suspected lack of efficacy on a Yellow Card (<a target=\"_blank\" href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/www.mhra.gov.uk/yellowcard\">www.mhra.gov.uk/yellowcard</a>)</li>\n</ul>\n</div>\n\n<p>*Please liaise with your wholesaler or arrange for uplift via Teva&#8217;s Customer Liaison team (0800 590 502) in the usual manner if you wish to return the Teva /Numark levothyroxine 100 microgram packs.</p>\n\n<p><strong>Further information:</strong></p>\n\n<p>Central Alerting System alert for the <a target=\"_blank\" href=\"https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101734\">suspension of Teva levothyroxine 100 microgram tablets</a> (issued 16th February 2012)</p>\n\n<p>MHRA <a target=\"_blank\" href=\"http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON143688\">press release</a> on suspension of Teva levothyroxine</p>\n\n<p><a target=\"_blank\" href=\"http://www.mhra.gov.uk/home/groups/comms-po/documents/news/con143690.pdf\">Q&amp;A document</a> on Teva levothyroxine suspension</p>\n\n<p><em>Article citation: Drug Safety Update March 2012, vol 5 issue 8: S1.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2012-03-01", 
  "date_last_modified": "2012-03-08", 
  "_assets": [
    {
      "content_type": "application/pdf", 
      "title": "Q&A document", 
      "assetid": 0, 
      "original_url": "http://www.mhra.gov.uk/home/groups/comms-po/documents/news/con143690.pdf", 
      "filename": "downloads/cbdea259e191a04bda6a2e96aa4fea4710d1ad09/con143690.pdf", 
      "original_filename": "con143690.pdf"
    }
  ], 
  "_item_id": 120, 
  "summary": "", 
  "body": "Article date: March 2012\n\nFollowing a review by the Commission on Human Medicines (CHM), the marketing authorisation (licence) for levothyroxine 100 microgram tablets manufactured by Teva has been suspended. The CHM review examined sporadic reports of potential reduced efficacy when switching to Teva levothyroxine from other levothyroxine products and evidence of manufacturing difficultiesAs a precautionary measure while investigations are ongoing, Teva has ceased manufacture and distribution of levothyroxine 100 microgram tablets. Only the Teva and Numark brands of this product are affected by the suspension.\n\nTeva levothyroxine 100 microgram tablets will cease to be available in the UK within the next few weeks, and no further supplies of this product will be released for marketing. Teva is accepting returned stock via the normal channels if it is not required to meet patient needs*. Other levothyroxine 100 microgram products will continue to be available.\n\nAdvice for healthcare professionals:  \n  \n  * Prescribers should be alert to the possibility that a change in a patient’s symptoms and TSH status may be attributed to switching to Teva product from another levothyroxine product  \n  * Certain patient groups such as pregnant women, patients with heart disease, and patients receiving treatment with levothyroxine following treatment for thyroid cancer should be monitored closely. If taking Teva tablets, they should have an early appointment with their doctor for a clinical review and blood test  \n  * The majority of patients will be able to continue with their medication and change to a different levothyroxine product at their next prescription  \n  * Patients who experience a significant change in symptoms especially after switching should have their TSH status reviewed and their dose of levothyroxine adjusted accordingly  \n  * You can report suspected lack of efficacy on a Yellow Card ([www.mhra.gov.uk/yellowcard](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/www.mhra.gov.uk/yellowcard))  \n  \n*Please liaise with your wholesaler or arrange for uplift via Teva’s Customer Liaison team (0800 590 502) in the usual manner if you wish to return the Teva /Numark levothyroxine 100 microgram packs.\n\nFurther information:\n\nCentral Alerting System alert for the [suspension of Teva levothyroxine 100 microgram tablets](https://www.cas.dh.gov.uk/ViewandAcknowledgment/ViewAlert.aspx?AlertID=101734) (issued 16th February 2012)\n\nMHRA [press release](http://www.mhra.gov.uk/NewsCentre/Pressreleases/CON143688) on suspension of Teva levothyroxine\n\n[ASSET_TAG](#ASSET0) on Teva levothyroxine suspension\n\nArticle citation: Drug Safety Update March 2012, vol 5 issue 8: S1.\n"
}